KANG [iKang Healthcare] 20-F: FORM 20-F (Mark One) o OR x OR

[FORM 20-F (Mark One) o OR x OR o OR o Date of event requiring this shell company report. . . . . . . . . . . . . . . . . . . . For the transition period from to iKang Healthcare Group, Inc. N/A Cayman Islands (Jurisdiction of incorporation or organization) B-6F, Shimao Tower 92A] [New China Life Insurance Co., Ltd. (“NCI”), iKang Guobin Healthcare Group Co., Ltd. (“iKang”), Shenzhen Top Spring Pu Chang Investment Management Co., Ltd. (“Top Spring Pu Chang”) and New China Life Insurance Health Investment Management Co., Ltd. (the “Target Company”) entered into the Capital Injection Agreement (the “Agreement”) on December 4, 2015, as supplemented by the Supplemental Agreement to the] [iKang Healthcare Technology Group Co., Ltd. (the “Borrower”) and AVIC Trust Co., Ltd. (the “Lender”) entered into the Loan Agreement (the “Agreement”) on December 9, 2015. Article 1. The Loan Amount The amount of loan (“Loan”) hereunder is RMB500,000,000. Article 2. Usage of the Loan. 2.1 2.2 Article 3. Term of the Loan. 3.1 3.2 1 3.3 3.4 3.5 3.6] [Shenzhen Xingwang Great Health No.1 Investment Center (Limited Partnership) (“Party A”) and iKang Healthcare Technology Group Co., Ltd. (“Party B”, or the “Company”) entered into the Investment Agreement on December 7, 2015, as supplemented by the Supplemental Agreement to the Investment Agreement dated February 14, 2016. Article 1. Terms of Loan and Conversion (1) (2) (3) (4) (5) (i) 1] [Zhongjin Zhide Equity Investment Management Co., Ltd. (“Party A”) and iKang Healthcare Technology Group Co., Ltd. (“Party B”, or the “Company”) entered into the Investment Agreement on December 11, 2015. Article 1. Terms of Loan and Conversion (1) (2) (3) (4) (5) 1 (i) (ii) (1) (2) (3) (4) 2 (5) Article 4. Event of Default (1) (2) (3) (4)] [Tianjin Junlian Yunpeng Enterprise Management Consulting Partnership (Limited Partnership) (“Party A”), iKang Healthcare Technology Group Co., Ltd. (“Party B”, or the “Company”) and Beijing Junlian Xinhai Equity Investment Partnership (Limited Partnership) (“Party C”) entered into the Investment Agreement on December 30, 2015, as supplemented by the Supplemental Agreement to the Investment Agreement dated February 14, 2016. Article 1. Terms of] [List of Subsidiaries Subsidiaries Place of Incorporation iKang Guobin Healthcare Group, Inc. British Virgin Islands iKang Zhejiang, Inc. British Virgin Islands iKang MRI Center, Inc. British Virgin Islands iKang mHealth, Inc. British Virgin Islands Yuanhua Healthcare Limited Hong Kong MediFast (Hong Kong) Limited Hong Kong Medifast (Hong Kong) Ltd. (Causeway Bay Branch) Hong Kong Medifast (Hong Kong) Ltd. (Kowloon Branch)] [I, Ligang Zhang, certify that: 1. I have reviewed this annual report on Form 20-F of iKang Healthcare Group, Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [Certification by the Principal Financial Officer I, Yang Chen, certify that: 1. I have reviewed this annual report on Form 20-F of iKang Healthcare Group, Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. July 29, 2016 EX-13.1 10 a16-11673_1ex13d1.htm EX-13.1] [Certification by the Principal Financial Officer (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. July 29, 201 EX-13.2 11 a16-11673_1ex13d2.htm EX-13.2] [15.1 29 July, 2016 Matter No.:823187 Doc Ref: 102708437 +852 2842 9531 Anna.Chong@conyersdill.com Charissa.Ball@conyersdill.com The Directors iKang Healthcare Group, Inc. B-6F Shimao Tower 92A Jianguo Road Chaoyang District Beijing 100022 People’s Republic of China Dear Sirs, Re: iKang Healthcare Group, Inc. (the “Company”) Form 20-F Yours faithfully, EX-15.1 12 a16-11673_1ex15d1.htm EX-15.1] [July 29, 2016 iKang Healthcare Group, Inc. B-6F Shimao Tower, 92A Jianguo Road Chaoyang District Beijing 100022 People’s Republic of China Ladies and Gentlemen, We consent to the reference to our firm under the captions of “Item 3.D — Risk Factors” and “Item 4.C — Organizational Structure” in iKang Healthcare Group, Inc.’s annual report on Form 20-F for the year] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements No. 333-197289 and Beijing, the People’s Republic of China July 29, 2016 EX-15.3 14 a16-11673_1ex15d3.htm EX-15.3]

By | 2016-08-02T13:06:53+00:00 July 29th, 2016|Categories: Chinese Stocks, KANG, Webplus ver|Tags: , , , , , |0 Comments
Read More

EFUT [eFuture] 6-K: (Original Filing)

[eFuture Announces Unaudited Second Quarter 2016 Financial Results BEIJING, July 30, 2016 (GLOBE NEWSWIRE) -- eFuture Holding Inc. (Nasdaq:EFUT) (the “Company” or “eFuture”), a leading software and solution provider and a mobile business enabler to China's retail and consumer goods industries, today announced its unaudited financial results for the second quarter ended June 30, 2016. Second Quarter 201 6 Financial] [Form 6-K 001-33113 eFuture Holding Inc. Room A1103, A1105, A1106-07, Building A, Note: Note: eFuture Holding Inc. Kevin King Chairman 6-K 1 f6k_072916.htm FORM 6-K]

By | 2016-08-02T13:09:01+00:00 July 29th, 2016|Categories: Chinese Stocks, EFUT, SEC Original|Tags: , , , , , |0 Comments
Read More

EFUT [eFuture] 6-K: eFuture Announces Unaudited Second Quarter 2016 Financial Results

[eFuture Announces Unaudited Second Quarter 2016 Financial Results BEIJING, July 30, 2016 (GLOBE NEWSWIRE) -- eFuture Holding Inc. (Nasdaq:EFUT) (the “Company” or “eFuture”), a leading software and solution provider and a mobile business enabler to China's retail and consumer goods industries, today announced its unaudited financial results for the second quarter ended June 30, 2016. Second Quarter 201 6 Financial] [Form 6-K 001-33113 eFuture Holding Inc. Room A1103, A1105, A1106-07, Building A, Note: Note: eFuture Holding Inc. Kevin King Chairman 6-K 1 f6k_072916.htm FORM 6-K]

By | 2016-08-02T13:10:05+00:00 July 29th, 2016|Categories: Chinese Stocks, EFUT, Webplus ver|Tags: , , , , , |0 Comments
Read More

CO [China Cord Blood] 20-F: (Original Filing)

[FORM 20-F o OR x OR o For the transition period from to OR o Date of event requiring this shell company report: China Cord Blood Corporation Cayman Islands (Jurisdiction of incorporation or organization) 48 th Floor, Bank of China Tower 1 Garden Road Central, Hong Kong S.A.R. Albert Chen +852 3605 8180 albert.chen@chinacordbloodcorp.com 48 th Floor, Bank of China] [List of Subsidiaries Name Jurisdiction China Cord Blood Services Corporation Cayman Islands China Stem Cells Holdings Limited Cayman Islands Beijing Jiachenhong Biological Technologies Co., Ltd. People’s Republic of China Guangzhou Municipality Tianhe Nuoya Bio-engineering Co., Ltd. People’s Republic of China Zhejiang Lukou Biotechnology Co., Ltd. People’s Republic of China China Stem Cells (East) Company Limited British Virgin Islands China Stem] [Certification I, Ting Zheng, certify that: 1. I have reviewed this annual report on Form 20-F of China Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [Certification I, Albert Chen, certify that: 1. I have reviewed this annual report on Form 20-F of China Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [Certification CHINA CORD BLOOD CORPORATION July 28, 2016 Ting Zheng Chief Executive Officer July 28, 2016 Albert Chen Chief Financial Officer (Principal Financial Officer) EX-13.1 5 a16-7975_1ex13d1.htm EX-13.1] [Consent of Independent Registered Public Accounting Firm The Board of Directors We consent to the incorporation by reference in the registration statements No. 333-183143 and No. 333-191121 on Form F-3 of China Cord Blood Corporation of our report dated July 31, 2015, with respect to the consolidated balance sheet of China Cord Blood Corporation and subsidiaries as of March 31,] [Consent of Independent Registered Public Accounting Firm The Board of Directors We consent to the incorporation by reference in the registration statements No. 333-183143 and No. 333-191121 on Form F-3 of China Cord Blood Corporation of our reports dated July 28, 2016, with respect to the consolidated balance sheet of China Cord Blood Corporation and subsidiaries as of March 31,] [Letter from Independent Registered Public Accounting Firm Ladies and Gentlemen: We were previously principal accountants for China Cord Blood Corporation and, under the date of July 31, 2015, we reported on the consolidated financial statements of China Cord Blood Corporation as of March 31, 2014 and 2015 and for each of the years in the three-year period ended March 31,]

By | 2016-08-02T11:38:49+00:00 July 28th, 2016|Categories: Chinese Stocks, CO, SEC Original|Tags: , , , , , |0 Comments
Read More

CO [China Cord Blood] 20-F: FORM 20-F o OR x OR o For

[FORM 20-F o OR x OR o For the transition period from to OR o Date of event requiring this shell company report: China Cord Blood Corporation Cayman Islands (Jurisdiction of incorporation or organization) 48 th Floor, Bank of China Tower 1 Garden Road Central, Hong Kong S.A.R. Albert Chen +852 3605 8180 albert.chen@chinacordbloodcorp.com 48 th Floor, Bank of China] [List of Subsidiaries Name Jurisdiction China Cord Blood Services Corporation Cayman Islands China Stem Cells Holdings Limited Cayman Islands Beijing Jiachenhong Biological Technologies Co., Ltd. People’s Republic of China Guangzhou Municipality Tianhe Nuoya Bio-engineering Co., Ltd. People’s Republic of China Zhejiang Lukou Biotechnology Co., Ltd. People’s Republic of China China Stem Cells (East) Company Limited British Virgin Islands China Stem] [Certification I, Ting Zheng, certify that: 1. I have reviewed this annual report on Form 20-F of China Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [Certification I, Albert Chen, certify that: 1. I have reviewed this annual report on Form 20-F of China Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [Certification CHINA CORD BLOOD CORPORATION July 28, 2016 Ting Zheng Chief Executive Officer July 28, 2016 Albert Chen Chief Financial Officer (Principal Financial Officer) EX-13.1 5 a16-7975_1ex13d1.htm EX-13.1] [Consent of Independent Registered Public Accounting Firm The Board of Directors We consent to the incorporation by reference in the registration statements No. 333-183143 and No. 333-191121 on Form F-3 of China Cord Blood Corporation of our report dated July 31, 2015, with respect to the consolidated balance sheet of China Cord Blood Corporation and subsidiaries as of March 31,] [Consent of Independent Registered Public Accounting Firm The Board of Directors We consent to the incorporation by reference in the registration statements No. 333-183143 and No. 333-191121 on Form F-3 of China Cord Blood Corporation of our reports dated July 28, 2016, with respect to the consolidated balance sheet of China Cord Blood Corporation and subsidiaries as of March 31,] [Letter from Independent Registered Public Accounting Firm Ladies and Gentlemen: We were previously principal accountants for China Cord Blood Corporation and, under the date of July 31, 2015, we reported on the consolidated financial statements of China Cord Blood Corporation as of March 31, 2014 and 2015 and for each of the years in the three-year period ended March 31,]

By | 2016-08-02T11:40:07+00:00 July 28th, 2016|Categories: Chinese Stocks, CO, Webplus ver|Tags: , , , , , |0 Comments
Read More

CO [China Cord Blood] 20-F: FORM 20-F o OR x OR o For

[FORM 20-F o OR x OR o For the transition period from to OR o Date of event requiring this shell company report: China Cord Blood Corporation Cayman Islands (Jurisdiction of incorporation or organization) 48 th Floor, Bank of China Tower 1 Garden Road Central, Hong Kong S.A.R. Albert Chen +852 3605 8180 albert.chen@chinacordbloodcorp.com 48 th Floor, Bank of China] [List of Subsidiaries Name Jurisdiction China Cord Blood Services Corporation Cayman Islands China Stem Cells Holdings Limited Cayman Islands Beijing Jiachenhong Biological Technologies Co., Ltd. People’s Republic of China Guangzhou Municipality Tianhe Nuoya Bio-engineering Co., Ltd. People’s Republic of China Zhejiang Lukou Biotechnology Co., Ltd. People’s Republic of China China Stem Cells (East) Company Limited British Virgin Islands China Stem] [Certification I, Ting Zheng, certify that: 1. I have reviewed this annual report on Form 20-F of China Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [Certification I, Albert Chen, certify that: 1. I have reviewed this annual report on Form 20-F of China Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [Certification CHINA CORD BLOOD CORPORATION July 28, 2016 Ting Zheng Chief Executive Officer July 28, 2016 Albert Chen Chief Financial Officer (Principal Financial Officer) EX-13.1 5 a16-7975_1ex13d1.htm EX-13.1] [Consent of Independent Registered Public Accounting Firm The Board of Directors We consent to the incorporation by reference in the registration statements No. 333-183143 and No. 333-191121 on Form F-3 of China Cord Blood Corporation of our report dated July 31, 2015, with respect to the consolidated balance sheet of China Cord Blood Corporation and subsidiaries as of March 31,] [Consent of Independent Registered Public Accounting Firm The Board of Directors We consent to the incorporation by reference in the registration statements No. 333-183143 and No. 333-191121 on Form F-3 of China Cord Blood Corporation of our reports dated July 28, 2016, with respect to the consolidated balance sheet of China Cord Blood Corporation and subsidiaries as of March 31,] [Letter from Independent Registered Public Accounting Firm Ladies and Gentlemen: We were previously principal accountants for China Cord Blood Corporation and, under the date of July 31, 2015, we reported on the consolidated financial statements of China Cord Blood Corporation as of March 31, 2014 and 2015 and for each of the years in the three-year period ended March 31,]

By | 2016-08-02T11:40:56+00:00 July 28th, 2016|Categories: Chinese Stocks, CO, Webplus ver|Tags: , , , , , |0 Comments
Read More

CYD [CHINA YUCHAI INTERNATIONAL] 6-K: (Original Filing)

[CHINA YUCHAI INTERNATIONAL TO ANNOUNCE - Earnings Call to Begin at 8:00 A.M. EDT - Singapore, Singapore – July 28, 2016 50566156 http://www.cyilimited.com For all other interested parties, a simultaneous webcast can be accessed at the investor relations section of the Company’s website located at About China Yuchai International http://www.cyilimited.com China Yuchai International Limited, through its subsidiary, Guangxi Yuchai Machinery] [FORM 6-K July 28, 2016 China Yuchai International Limited ——————————————————————————————————— 16 Raffles Quay #26-00 ——————————————————————————————————— x x n/a China Yuchai International Limited Weng Ming Hoh President/Director Description 99.1 Press release dated July 28, 2016 - China Yuchai International to Announce Unaudited Second Quarter 2016 Financial Results on August 11 6-K 1 htm_10370.htm LIVE FILING]

By | 2016-08-02T11:47:43+00:00 July 28th, 2016|Categories: Chinese Stocks, CYD, SEC Original|Tags: , , , , , |0 Comments
Read More

CYD [CHINA YUCHAI INTERNATIONAL] 6-K: CHINA YUCHAI INTERNATIONAL TO ANNOUNCE – Earnings Call

[CHINA YUCHAI INTERNATIONAL TO ANNOUNCE - Earnings Call to Begin at 8:00 A.M. EDT - Singapore, Singapore – July 28, 2016 50566156 http://www.cyilimited.com For all other interested parties, a simultaneous webcast can be accessed at the investor relations section of the Company’s website located at About China Yuchai International http://www.cyilimited.com China Yuchai International Limited, through its subsidiary, Guangxi Yuchai Machinery] [FORM 6-K July 28, 2016 China Yuchai International Limited ——————————————————————————————————— 16 Raffles Quay #26-00 ——————————————————————————————————— x x n/a China Yuchai International Limited Weng Ming Hoh President/Director Description 99.1 Press release dated July 28, 2016 - China Yuchai International to Announce Unaudited Second Quarter 2016 Financial Results on August 11 6-K 1 htm_10370.htm LIVE FILING]

By | 2016-08-02T11:48:35+00:00 July 28th, 2016|Categories: Chinese Stocks, CYD, Webplus ver|Tags: , , , , , |0 Comments
Read More
Skip to toolbar